SGMO
Sí, esa ha sido la estrategia buena hasta ahora, al menos para tradear con una parte.
Tuvo resultados aparentemente no muy buenos y por eso b2k ha actualizado su valuación (incluso puede que se las quite, se lo está pensando). De hecho, va a reestructurar su cartera y vender algunas como GTHX, MRKR, KURA y ALLO.
Respecto a SGMO, you he completado de nuevo esta semana los 400 cromos que tan mal vendí a $8.46. Visto lo visto, también, recomprados reguleramente, tendré que añadir más riesgo y cromos si quiero bajar la media. Al final break even a casi $12 y la compra $1.5 más cara que la última venta...
b2k rating:
Slashing my rating and numbers for SGMO
I reduce my valuation for Beta Thal and SCD to $0. That program will be an epic fail just like MPS I. I now believe zinc fingers are not efficient at editing. This makes all their science based on zinc fingers broken. I would hope that Znic Finger 2.0 can solve these problem, but I have little hope. I hope they will drop gene editing and embrace gene therapies. This company has so much bloated people in it for costs. They have assistants to assistants. They need a huge cutting of the fat. Half these people should get pink slips for Christmas. This is officially a broken company and no longer just a broken stock. I will give them through R&D day to tell me they know the problems and plan to fix them or its gone.
1. Management - Sandy Macrae - 3 Stars
- Integrity - 3 Stars
- Communicator - 3 Stars
- Financial Manager - 3 Stars
- Regulatory Affairs - 3 Stars
- Good Decision Making - 3 Stars
2. Science - 3.25 Stars
- Breakthrough Therapies - 4 Stars (1 RMAT Designation)
- Diversified Pipeline - 5 Stars (7 drugs)
- Stage of Development - 3 Stars (Phase 2)
- Clinical Success - 1 Stars (4 clinical failures)
3. Potential - 5 stars (+864% over 12 years = 72% annual)
Gene Therapies
SB-525 (Hemophilia A) - $330 million @ 15% royalty Pfizer
ST-920 Fabry - $1.5 billion
Ex-Vivo Cell Therapies
ST-400 - $0 @ 15% royalty Sanofi (Failed)
BIVV-003 - $0 @ 15% royalty Sanofi (Failed)
Tx-200 - $250 million
CAR-T - $50 million @ 5% royalty Gilead
In-Vivo Gene editing
SB-318 - $0 (Failed)
SG-913 - $0 (Failed)
SB-FIX - $0
In-Vivo Gene Regulation
Tau - $250 million
ALS - $30 Million @ 7.5% royalty Pfizer
Huntington's - ?
Total Peak Sales = $2.41 billion * 4 P/S = $9.6 billion Market Cap peak
4. Valuation – 5 Stars (Very Cheap)
Gene Therapies
SB-525 - $330 million * 2 for phase 2 = $ 660 million value
ST-920- $1.5 billion * 10% for starting phase 1 = $150 million value
Ex-Vivo Cell Therapies
ST-400 - $0 value
BIVV-003 - $0 value
T-reg - $250 million * 10% for early phase 1 = $25 million value
CAR-T - $50 million * 10% for early phase 1 = $5 million value
In-Vivo Gene Editing
SB-318 - $0 value
SB-913 - $0 value
SB-FIX - $0 value
In-Vivo Gene Regulation
Tau - $250 million * 10% for preclinic = $25 million value
ALS - $30 Million * 10% for preclinic = $3 million value
Huntington's - ?
Cash = $408 million
Total Value = $1.276 billion vs $1 billion Market Cap = -21% (Very Cheap)
Around $11 with 116M shares
5. Financials - 4 stars (Not Profitable Yet)
Cash = $408 million
Cash Burn = $27 million per quarter
More than 2 years cash
Total Ranking: 4.05 stars
